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Purpose
The deregulation of the Def6-ROCK2-IRF4 axis in mur-
ine models results in both lupus-like and rheumatoid
arthritis-like disease characterized by increased IL-17
and IL-21 production that is ameliorated by ROCK inhi-
bition. A known beneficial pleiotropic effect of statins is
inhibition of ROCK activation via their effect on RhoA
activation. Statins have also been reported to decrease
IL-17 and IL-21 production in T cells. Whether statins
exert their inhibitory effects by interfering with the
ROCK2-IRF-4 interaction in CD4+ T cells is unknown.
The aim of the present study is to investigate whether
statins can inhibit the ROCK pathway in CD4+ T cells
and inhibit IL-17 and IL-21 production.
Methods
Purified CD4+ T cells from the spleens and lymph nodes
of wild type and Def6-deficient DO11.10 transgenic mice
were stimulated with aCD3 and aCD28 in the presence/
absence of simvastatin (1-10μM) with and without the
known ROCK inhibitor, Y-27632 (10-30μM). Supernatants
were collected and IL-17 and IL-21 production analyzed
by ELISA.
Results
As previously reported, Def6-deficient CD4+ T cells
secreted significantly higher levels of IL-17 and IL-21
when stimulated as compared to wild type controls, which
was ameliorated by addition of the ROCK inhibitor, Y-
27632. Simvastatin significantly decreased the concentra-
tions of IL-17 and IL-21 at all tested concentrations in a
dose dependent manner (p<.05). At lower concentrations
of simvastatin (<2.5μM), the addition of Y-27632 further
decreased cytokine production.
Conclusion
These data suggest that simvastatin can interfere with the
ROCK pathway in CD4+ T cells and inhibit IL-17 and IL-
21 production in a murine model of autoimmunity. As
statins and ROCK inhibitors have distinct targets, our data
furthermore suggest that combination therapy with a sta-
tin and a ROCK inhibitor may be more effective than
monotherapy. Furthermore, we speculate that the decrease
in cytokines is linked to a decrease in the phosphorylation
status of IRF4 and its ability to target the promoters of
these cytokines.
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